Cargando…
Efficacy of daratumumab in refractory primary Sjögren disease
Autores principales: | Nocturne, Gaetane, Marmontel, Oriane, di Filippo, Mathilde, Chretien, Pascale, Krzysiek, Roman, Lifermann, Francois, Rahal, Nawal, Belkhir, Rakiba, Moulin, Philippe, Mariette, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510860/ https://www.ncbi.nlm.nih.gov/pubmed/37730313 http://dx.doi.org/10.1136/rmdopen-2023-003464 |
Ejemplares similares
-
Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019) -
Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022) -
Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019) -
Normal salivary gland ultrasonography could rule out the diagnosis of Sjögren’s syndrome in anti-SSA-negative patients with sicca syndrome
por: Al Tabaa, Omar, et al.
Publicado: (2021) -
Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)